Overview

Study to Evaluate the Efficacy and Safety of Docetaxel Polymeric Micelle (PM) in Recurrent or Metastatic HNSCC

Status:
Unknown status
Trial end date:
2020-09-01
Target enrollment:
Participant gender:
Summary
A phase II study to evaluate the efficacy and safety of Docetaxel-PM in recurrent or metastatic head and neck squamous cell carcinoma
Phase:
Phase 2
Details
Lead Sponsor:
Samyang Biopharmaceuticals Corporation
Treatments:
Docetaxel